Difesa Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Difesa Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-551,435	Closed	-$10.5K	–	209
2023 Q1	$10.5K	Buy	551,435 +250,000	+83%	+$24.1K	0.01%	129
2022 Q4	$44.9K	Buy	301,435 +150,000	+99%	+$24K	0.03%	103
2022 Q3	$26K	Hold	151,435	–	–	0.01%	139
2022 Q2	$19K	Buy	151,435 +1,435	+1%	+$709	0.01%	156
2022 Q1	$119K	Hold	150,000	–	–	0.06%	134
2021 Q4	$90K	Buy	+150,000	New	+$152K	0.06%	131

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Difesa Capital Management's PEARW Position: Q2 2023 in Review

Difesa Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 551,435 shares — an estimated $10.5K sold.

Difesa Capital Management first reported a position in PEARW in Q4 2021 and held it in 6 quarters. The position peaked at $119K in Q1 2022. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Difesa Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Difesa Capital Management sold 551,435 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $10.5K.
Difesa Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q4 2021 and held it in 6 quarters.
Difesa Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $119K in Q1 2022.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Difesa Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.